Wu P B, Song Q, Yu Y J, Yu H G, Luo H S, Tan S Y
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Digestive Diseases, Wuhan 430060, China.
Zhonghua Gan Zang Bing Za Zhi. 2020 Jan 20;28(1):64-68. doi: 10.3760/cma.j.issn.1007-3418.2020.01.015.
To investigate the effects of metformin on mitochondrial pathway of apoptosis and oxidative stress in cell model of nonalcoholic fatty liver disease. An in vitro cell model of nonalcoholic fatty liver disease was established using 0.6 mmol/L oleic acid to induce lipid accumulation in HepG2 cells. HepG2 cells were divided into control (Con) group, oleic acid (OA) group, and metformin-low (1mmol/L) and high (10mmol/L) dose group. Oil Red O stain was used to detect intracellular lipid droplet distribution. The levels of alanine aminotransferase and aspartate aminotransferase in the culture supernatant were detected by assay kits. DCFH-DA method was used to detect the reactive oxygen species of HepG2 cells. Double staining flow cytometry was used to detect the apoptosis rate of HepG2 cells. Western blot was used to detect caspase-3, B-lymphocyte lymphoma-related protein, B-cell lymphoma 2, and cytochrome c protein. One-way analysis of variance was used to compare the data between groups. Oleic acid-induced HepG2 cells were significantly increased with lipid droplets. Low and high-dose metformin had reduced intracellular lipid droplets accumulation. The effect of metformin in the high-dose group was more significant than that in the low-dose group. Aspartate aminotransferase and alanine aminotransferase in HepG2 cells of OA group were significantly increased, which were (43.41 ± 7.11) U/L and (29.56 ± 4.11) U/L, respectively. The intracellular aspartate aminotransferase and alanine aminotransferase were decreased significantly after the treatment with low and high-dose metformin, which were (32.44 ± 4.08)U/L, (19.31 ± 3.03) U/L, (26.00 ± 3.11) U/L and (15.11 ± 4.11) U/L, respectively and the differences were statistically significant ( < 0.05). DCFH-DA test results showed that the fluorescence intensity of reactive oxygen species in the oleic acid group was 41.21% ± 4.23%, while the fluorescence intensity of reactive oxygen species in the low and high-dose metformin groups were reduced to 27.44% ± 3.91%, and 17.55% ± 5.11%, respectively and the differences between the groups were statistically significant ( < 0.05). The results of flow cytometry analysis showed that the cell apoptosis rate of the OA group was significantly higher than that of the Con group (12.12% ± 0.72% vs. 3.04% ± 0.57%, < 0.05).The apoptosis rate of HepG2 cells was significantly reduced after metformin treatment at low and high doses (8.71% ± 0.71%, 5.71% ± 0.61%, < 0.05). Western blot results showed that compared with the Con group, the expressions of B-lymphocyte lymphoma-related protein, cytochrome c, and caspase-3 were increased in the OA group, while the B-cell lymphoma 2 were decreased ( < 0.05). The expression of B-lymphocyte lymphoma-related protein, cytochrome c, and caspase-3 protein in HepG2 cells was decreased after treatment with low and high-dose metformin, while B-cell lymphoma 2 was increased ( < 0.05). Metformin can effectively alleviate steatosis and improve the HepG2 function in cell model of nonalcoholic fatty liver disease. The mechanism of metformin may be related to the reduction of oxidative stress injury, the regulation of protein expression related to mitochondrial apoptosis pathway and the inhibition of cell apoptosis.
探讨二甲双胍对非酒精性脂肪性肝病细胞模型中细胞凋亡线粒体途径及氧化应激的影响。采用0.6 mmol/L油酸诱导HepG2细胞脂质蓄积,建立非酒精性脂肪性肝病体外细胞模型。将HepG2细胞分为对照组(Con)、油酸(OA)组、二甲双胍低剂量(1 mmol/L)组和高剂量(10 mmol/L)组。采用油红O染色检测细胞内脂滴分布。用试剂盒检测培养上清液中丙氨酸氨基转移酶和天冬氨酸氨基转移酶水平。采用DCFH-DA法检测HepG2细胞活性氧。采用双染色流式细胞术检测HepG2细胞凋亡率。采用蛋白质免疫印迹法检测半胱天冬酶-3、B淋巴细胞淋巴瘤相关蛋白、B细胞淋巴瘤-2及细胞色素c蛋白。采用单因素方差分析比较组间数据。油酸诱导的HepG2细胞脂滴明显增多。低、高剂量二甲双胍均可减少细胞内脂滴蓄积,高剂量组二甲双胍的作用更显著。OA组HepG2细胞中天冬氨酸氨基转移酶和丙氨酸氨基转移酶显著升高,分别为(43.41±7.11)U/L和(29.56±4.11)U/L。低、高剂量二甲双胍处理后,细胞内天冬氨酸氨基转移酶和丙氨酸氨基转移酶显著降低,分别为(32.44±4.08)U/L、(19.31±3.03)U/L、(26.00±3.11)U/L和(15.11±4.11)U/L,差异有统计学意义(P<0.05)。DCFH-DA检测结果显示,油酸组活性氧荧光强度为41.21%±4.23%,低、高剂量二甲双胍组活性氧荧光强度分别降至27.44%±3.91%和17.55%±5.11%,组间差异有统计学意义(P<0.05)。流式细胞术分析结果显示,OA组细胞凋亡率显著高于Con组(12.12%±0.72%比3.04%±0.57%,P<0.05)。低、高剂量二甲双胍处理后,HepG2细胞凋亡率显著降低(8.71%±0.71%,5.71%±0.61%,P<0.05)。蛋白质免疫印迹结果显示,与Con组比较,OA组B淋巴细胞淋巴瘤相关蛋白、细胞色素c及半胱天冬酶-3表达增加,B细胞淋巴瘤-2表达降低(P<0.05)。低、高剂量二甲双胍处理后,HepG2细胞中B淋巴细胞淋巴瘤相关蛋白、细胞色素c及半胱天冬酶-3蛋白表达降低,B细胞淋巴瘤-2表达增加(P<0.05)。二甲双胍可有效减轻非酒精性脂肪性肝病细胞模型中的脂肪变性,改善HepG2功能。其机制可能与减轻氧化应激损伤、调节线粒体凋亡途径相关蛋白表达及抑制细胞凋亡有关。